Drug updated on 3/28/2024
| Dosage Form | Tablet (oral: 50 mg, 150 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
- Indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
Summary
- Tucatinib (Tukysa) is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases who have received one or more prior anti-HER2-based regimens in a metastatic setting.
- Additionally, tucatinib (Tukysa) is also used alongside trastuzumab to treat adults suffering from RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment involving fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
- A total of 3 systematic reviews/meta-analyses were reviewed which revealed that therapy using tyrosine kinase inhibitors like tucatinib improved survival outcomes for HER2-positive breast cancer patients having brain metastases, especially when combined with capecitabine; this regimen was associated with tolerable adverse events such as diarrhea, neutropenia, hepatic toxicity and sensory neuropathy.
- The network meta-analysis ranked tucatinib plus trastuzumab alongwith capecitabine highest both in terms of progression-free survival (PFS) and overall survival (OS), followed by T-DM1 monotherapy among therapies administered to patients suffering from HER+ unresectable/metastatic breast cancer after at least one round of previous therapy targeting the same receptor type.
- In comparison to lapatanib/trustzumam plus capcitabinbe treatments not targeted specifically towards any receptors,T-DM1 monotherapy consistently showed better PFS and OS results when used together with tucitanub plus trustzumanb alongwith capecaitinabe.
- However no specific information regarding population types or subgroup considerations was provided within these documents hence further research may be required to determine the efficacy and safety of tucatinib (Tukysa) in diverse patient populations.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tukysa (tucatinib) Prescribing Information. | 2022 | Seagen Inc., Bothell, WA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO guideline update. | 2022 | Journal of Clinical Oncology |